16.	Related Party Transactions

Roche Holdings, Inc. and its affiliates

Related-party molecular information services revenue from Roche for the three and six months ended June 30, 2018 was $12,005,000 and $26,820,000, respectively, and $5,520,000 and $11,024,000 for the three and six months ended June 30, 2017, respectively, which was earned under the Molecular Information Platform Program and Ex-U.S. Commercialization Agreement.

Related-party pharma research and development services revenue from Roche for the three and six months ended June 30, 2018 was $2,567,000 and $4,034,000, respectively, and $3,492,000 and $7,635,000 for the three and six months ended June 30, 2017, respectively, from the reimbursement of R&D costs under the CDx Development, Immunotherapy Testing Platform Development and other programs.

Costs of related-party molecular information services from Roche were $4,800,000 and $10,748,000 for the three and six months ended June 30, 2018, respectively, and $2,045,000 and $2,945,000 for the three and six months ended June 30, 2017, respectively, which consisted of costs incurred under the Molecular Information Platform Program and costs related to the delivery of services outside of the United States under the Ex-U.S. Commercialization Agreement.

At June 30, 2018, $11,402,000 and $8,190,000 was included in total accounts receivable and deferred revenue, respectively, related to this arrangement with Roche. At December 31, 2017, $10,159,000 and $3,742,000 was included in total accounts receivable and deferred revenue, respectively, related to this arrangement with Roche. As of June 30, 2018, the Company had $110 million in borrowings outstanding under the Roche Credit Facility. There were no other material Roche-related balances included in the condensed consolidated financial statements as of June 30, 2018 or December 31, 2017, or for the three and six months ended June 30, 2018 and 2017.